Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab

Jonathan W. Friedberg, MD, Michael T. Brady, PhD, Myla Strawderman, MS, Brad S. Kahl, MD, John P. Leonard, MD, Izidore S. Lossos, MD, Christopher R. Flowers, MD MS, Grerk Sutamtewagul, MD, Jonathon B. Cohen, MDMS, Derick R. Peterson, PhD, Loretta J. Nastoupil, MD MSc

Blood (2019) 134 (Supplement_1): 4008.

https://doi.org/10.1182/blood-2019-127320

Published: 2019

Journal Articles

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Ran Reshef, MDMSc, David B. Miklos, MD PhD, John M. Timmerman, MD, Caron A. Jacobson, MD MMSc, Nabila N. Bennani, MD, John M. Rossi, MS, Marika Sherman, MS, Lianqing Zheng, PhD, Jennifer Sun, MS, Gabrielle Palluconi, BS, Jenny J. Kim, MD MS, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 4084.

https://doi.org/10.1182/blood-2019-123772

Published: 2019

Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell

Blood (2019) 134 (Supplement_1): 3801.

https://doi.org/10.1182/blood-2019-128511

Published: 2019

Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4006.

https://doi.org/10.1182/blood-2019-121936

Published: 2019

Journal Articles

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

Pedro Horna, MD, Grzegorz Nowakowski, MD, Jan Endell, Rainer Boxhammer

Blood (2019) 134 (Supplement_1): 5345.

https://doi.org/10.1182/blood-2019-129600

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

Wojciech Jurczak, Simon Rule, MD, William Townsend, MD FRCPath, David Tucker, Barbara Sarholz, Jürgen Scheele, John G. Gribben, Pier Luigi Zinzani, MD

Blood (2018) 132 (Supplement 1): 4161.

https://doi.org/10.1182/blood-2018-99-112808

Published: 2018

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Chronic Lymphocytic Lymphoma: Differences between Patients Treated with Ibrutinib or Bendamustine + Rituximab

Debra Irwin, Lu Zhang, ScD, Kathleen Wilson, MPH, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD

Blood (2018) 132 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2018-99-112626

Published: 2018

Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

Vinay Manu Daryani, PharmD, Shringi Sharma, PhD, Guan Xing, PhD, Jeffrey Silverman, PhD, Adeboye Henry Adewoye, MD, Anita Mathias, PhD

Blood (2017) 130 (Supplement 1): 5344.

https://doi.org/10.1182/blood.V130.Suppl_1.5344.5344

Published: 2017

Journal Articles

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

Sandra Lockmer, Bjorn Ostenstad, Hans Hagberg, Harald Holte, Björn Engelbrekt Wahlin, Chloe Beate Steen, Peter de Nully Brown, MD PhD, Eva Kimby

Blood (2017) 130 (Supplement 1): 2768.

https://doi.org/10.1182/blood.V130.Suppl_1.2768.2768

Published: 2017

Journal Articles

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Joseph Tuscano, MD, Susan Groshen, PhD, Denice Tsao-Wei, Emanual Maverakis, MD, Paul R. Kaesberg, MD, Tanya Siddiqi, MD, Leslie Popplewell**, MD, Sikander Ailawadhi, Myo Htut, Robert W. Chen, MD, Mark Kirschbaum, MD, Mark T. Schroeder, MD, Brian A Jonas, MD PhD, Ted Wun, MD FACP, FRCPA, Neil Palmisiano, MD, David F. Claxton, Edward Newman, PhD

Blood (2017) 130 (Supplement 1): 4086.

https://doi.org/10.1182/blood.V130.Suppl_1.4086.4086

Published: 2017

Journal Articles

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Abhijeet Kumar, MD, Jose Guillen-Rodriguez, Jonathan H. Schatz, MD, Lora Inclan, Alfonso E Ayala, Xavier Rivera, Srinath Sundararajan, MD, Faiz Anwer, MD, Daruka Mahadevan, MD PhD, Daniel O. Persky, MD, Soham D. Puvvada, MD

Blood (2016) 128 (22): 1790.

https://doi.org/10.1182/blood.V128.22.1790.1790

Published: 2016

Journal Articles

Neutrophil Engraftment and Graft-Versus-Host Disease in Elderly Patients Undergoing Hematopoietic Stem Cell Transplantation: Importance of Body Composition Assessment and Geriatric

Ludmila Koch, MD, Reynaldo Filho, MD PhD, Nelson Hamerschlak, MD PhD, Adham Castro, MD, Adriano Tachibana, MD, Cinthya Silva, Biomedical Chemist, Andrea Z Pereira, MD PhD

Blood (2016) 128 (22): 5808.

https://doi.org/10.1182/blood.V128.22.5808.5808

Published: 2016

Journal Articles

Prognostic Significance of Serum LDH in B Cell Chronic Lymphoproliferative Disorders: A Single-Institution Study of 829 Cases in China

Huimin Liu, Wenjie Xiong, Heng Li, Rui Lv, MD, PhD, Wei Liu, MD, PhD, Shuhua Yi, MD, PhD, Zengjun Li, MD, PhD, Lugui Qiu, MD

Blood (2016) 128 (22): 5336.

https://doi.org/10.1182/blood.V128.22.5336.5336

Published: 2016

Journal Articles

The Prognostic Value for Survival of Patient-Reported Outcomes in Hematological Malignancies: A Systematic Review

Avrita Campinha-Bacote, BS MPH, Peter C Trask, Fabio Efficace, PhD

Blood (2016) 128 (22): 4793.

https://doi.org/10.1182/blood.V128.22.4793.4793

Published: 2016

Journal Articles

Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies

Binod Dhakal, MD, Sridevi Ramalingam, MD, Jamie Shuff, MD, Narendranath Epperla, MD, Lisa Rein, MS, Anjishnu Banerjee, PhD, Malika Siker, MD, Paul R. Hosking, MD, Parameswaran Hari, MD MRCP, MS, Anita D'Souza, MBBS, MD, Ehab Atallah, MD, Beth Erisckson, MD, Timothy S. Fenske, MD, Mehdi Hamadani, MD

Blood (2015) 126 (23): 2711.

https://doi.org/10.1182/blood.V126.23.2711.2711

Published: 2015

Journal Articles

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

Ahmed Sawas, MD, Kerry J. Savage, MDMSc, Raymond Perez, MD, Ranjana H Advani, MD, Anna Butturini, MD, Jacqueline Lackey, Fabio Trave, MD, Banmeet Anand, PhD, Yao Huang, Leonard Reyno, MD, Owen A. O'Connor, MD

Blood (2015) 126 (23): 3976.

https://doi.org/10.1182/blood.V126.23.3976.3976

Published: 2015

Journal Articles

PD-L1 and PD1 Expression in Lymphomas

Zoran Gatalica, MD PhD, Nurija Bilalovic, MD PhD, Semir Vranic, MD PhD, David Arguello, MD, Sandeep Reddy, MD, Nilanjan Ghosh, MD PhD

Blood (2015) 126 (23): 3899.

https://doi.org/10.1182/blood.V126.23.3899.3899

Published: 2015

NARROW

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

Real-World Healthcare Resource Utilization in Patients with Chronic Lymphocytic Lymphoma: Differences between Patients Treated with Ibrutinib or Bendamustine + Rituximab

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Neutrophil Engraftment and Graft-Versus-Host Disease in Elderly Patients Undergoing Hematopoietic Stem Cell Transplantation: Importance of Body Composition Assessment and Geriatric

Prognostic Significance of Serum LDH in B Cell Chronic Lymphoproliferative Disorders: A Single-Institution Study of 829 Cases in China

The Prognostic Value for Survival of Patient-Reported Outcomes in Hematological Malignancies: A Systematic Review

Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

PD-L1 and PD1 Expression in Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only